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Abstract
Introduction—Actual 5-year survival rates of 10–18% have been reported for patients with
resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in
these series. We evaluated long-term survival and patterns of recurrence in patients treated for PC
with contemporary staging and multimodality therapy.
Methods—We analyzed 329 consecutive patients with PC evaluated between 1990 and 2002
who underwent resection. Each received a multidisciplinary evaluation and standard operative
approach. Pre- or postoperative chemotherapy and/or chemoradiation were routine. Surgical
specimens of 5-year survivors were rereviewed. A multivariate model of factors associated with
long-term survival was constructed.
Results—Patients underwent pancreaticoduodenectomy (n = 302; 92%), distal (n = 20; 6%), or
total pancreatectomy (n = 7; 2%). A total of 108 patients (33%) underwent vascular
reconstruction, 301 patients (91%) received neoadjuvant or adjuvant therapy, 157 specimens
(48%) were node positive, and margins were microscopically positive in 52 patients (16%).
Median overall survival and disease-specific survival was 23.9 and 26.5 months. Eighty-eight
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patients (27%) survived a minimum of 5 years and had a median overall survival of 11 years. Of
these, 21 (24%) experienced recurrence, 7 (8%) after 5 years. Late recurrences occurred most
frequently in the lungs, the latest at 6.7 years. Multivariate analysis identified disease-negative
lymph nodes (P = .02) and no prior attempt at resection (P = 0.01) as associated with 5-year
survival.
Conclusions—Our 27% actual 5-year survival rate for patients with resected PC is superior to
that previously reported, and it is influenced by our emphasis on detailed staging and patient
selection, a standardized operative approach, and routine use of multimodality therapy.
Surgical resection of the involved portion of pancreas has long been characterized as the
only potentially curative therapy for patients with pancreatic adenocarcinoma (PC).
Although removal of the primary tumor is necessary to ensure long-term survival, it is
usually not sufficient. Of the 10% of patients who seek care with anatomically localized,
stage I and II PC, surgical resection alone has been associated with a median survival of
only 11–20 months as a result of high rates of postoperative tumor recurrence.1–5 Such data
provide support for ongoing efforts to combine surgery with systemic therapies and
chemoradiation. For patients who have locally advanced (stage III) PC, complete resection
of the primary tumor is usually not possible, and for those with metastatic (stage IV) PC,
surgery directed at the primary tumor offers no clinical benefit. Therein lies the importance
of accurately defining the extent of disease at the time of diagnosis and reserving surgery for
those patients with localized, nonmetastatic PC who can undergo a complete gross resection
of the primary tumor.6,7
For patients with resectable PC, actual rates of long-term survival and systematic analyses of
clinicopathologic factors associated with it have only recently been published.8–14 Series of
long-term survivors published within the past decade demonstrate that 10–18% of patients
who have undergone resection for PC at major referral centers have survived at least 5 years.
However, most such patients were treated in an era in which pretreatment staging was
inferior to that available today, the use of adjuvant/neo-adjuvant therapy was uncommon,
and vascular resection and reconstruction at the time of pancreatectomy was rarely
performed.15 Moreover, these series often included patients with incompletely resected
locally advanced disease (grossly positive margins of resection, R2) and those with
metastatic disease not appreciated on preoperative imaging, in whom the postoperative
outcome is expected to be poor.16 Finally, the data presented in these reports were often
incomplete, particularly with regard to the timing and pattern of disease recurrence. Taken
together, these limitations make the conclusions drawn from prior studies of long-term,
postsurgical survival difficult to apply to patients treated with a more modern and systematic
multidisciplinary approach to their disease.
Over the past two decades, important advances in the perioperative management of patients
with PC have led to a reduction in the morbidity and mortality associated with pancreatic
surgery. In an attempt to further improve patient outcome, we and others have sought to
better define who should undergo surgery with a more objective definition of the term
resectable, to extend the limits of pancreaticoduodenectomy (PD) to include a standardized
approach to venous resection when needed, and to emphasize the routine use of combined
modality therapy.17–19
At our institution, the pretreatment staging evaluation, treatment, and follow-up of all
patients with PC is coordinated by a multidisciplinary working group that meets weekly and
is supported by an integrated database and tumor bank.20 Since 1990, we have used
standardized definitions and algorithms for clinical/radiographic staging, surgical technique,
and histopathologic analysis of surgical specimens. Recent outcome data have supported our
approach to venous resection and reconstruction when necessary to achieve a gross complete
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(R0, R1) resection.18 Finally, results from our clinical trials of neoadjuvant therapy followed
by surgery has led to an institutional bias toward this approach for patients with potentially
resectable (stage I and II) and borderline resectable (subgroup of stage III) PC; in the
absence of neoadjuvant therapy, postoperative adjuvant therapy has been used whenever
possible.21–27 Therefore, this report reflects a relatively homogenous population of
consecutive patients who have been accurately staged and treated in a uniform fashion. The
long-term outcomes reported herein accurately represent the natural history of disease in
patients with resectable pancreatic cancer treated with a multidisciplinary approach.
PATIENTS AND METHODS
All patients who underwent evaluation for presumed or biopsy-proven PC were treated by
members of our multidisciplinary pancreatic tumor study group in a disease-site-specific
gastrointestinal outpatient center staffed by surgical oncologists, medical oncologists, and
radiation oncologists. The treatment algorithm for each patient was established and
coordinated by the multidisciplinary team at a weekly meeting. All clinical data were
prospectively recorded in a database maintained in the Department of Surgical Oncology,
and corresponding biospecimens were preserved in an integrated tumor bank.20
Clinical data of all patients who underwent evaluation for presumed or biopsy-proven PC
between March 1990 and September 2002 and who underwent resection of their primary
tumor were reviewed. Patients with a final diagnosis of invasive intraductal papillary
mucinous neoplasm, mucinous cystadenocarcinoma, neuroendocrine carcinoma, or any
other nonpancreatic periampullary adenocarcinoma were specifically excluded from
analysis.
Staging
Only patients with tumors initially characterized as either resectable or borderline resectable
were considered for surgery. Staging was established by using a multidetector contrast-
enhanced computed tomographic (CT) scan of the abdomen and was confirmed when
necessary by multidisciplinary review. Resectable pancreatic cancer was anatomically
defined by the following: (1) absence of extrapancreatic disease; (2) no evidence of tumor
extension to the superior mesenteric artery (SMA), celiac axis, or hepatic artery as defined
by the presence of a tissue plane between the tumor and these arteries; and (3) a patent
superior mesenteric–portal vein (SMPV) confluence.28 Anatomically defined borderline
resectable tumors were those that demonstrated tumor abutment (180° or less of the
circumference of the vessel) of the SMA or celiac axis; tumor abutment or encasement
(>180° of the circumference of the vessel) of a short segment of the hepatic artery; or short-
segment occlusion of the superior mesenteric vein, portal vein, or SMPV confluence that
was amenable to vascular resection and reconstruction.17,29
Treatment Sequencing
For patients with resectable PC as defined above, we have had an institutional focus on the
development of clinical trials exploring the use of protocol-based neoadjuvant therapy
before surgical resection.22–24,26,27,30 In general, patients with resectable, biopsy proven
disease usually received neoadjuvant therapy either on or off protocol; if tissue confirmation
of disease was not obtained, then a surgery-first strategy was used. Patients who underwent
surgery first, followed by adjuvant chemoradiation and/or systemic chemotherapy, also
included those patients with resectable disease who required an urgent operation and those
patients who chose this treatment sequence. Although postoperative adjuvant therapy was
favored in these situations, it was not successfully delivered to all such patients.21 Patients
with borderline resectable anatomy, or those with findings indeterminate for distant
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metastases or with a marginal performance status received neoadjuvant therapy off
protocol.17
Neoadjuvant chemotherapy and/or chemoradiation was administered either at our institution
or under the care of the patient’s referring oncologist. The specific regimens have been
previously described in detail.22–24,30 Briefly, external-beam radiotherapy usually consisted
of 50.4 Gy in 28 fractions or 30 Gy in 10 fractions. Concomitant chemotherapy consisted of
5-fluorouracil, paclitaxel, gemcitabine, or capecitabine at radiosensitizing doses.
Chemotherapy, when delivered alone (usually before chemoradiation in the later part of the
study period examined herein), consisted of gemcitabine alone or in combination.
Approximately 4 to 6 weeks after the completion of all neoadjuvant treatment, patients
underwent restaging evaluation that included CT and a complete physiologic assessment to
determine their suitability for operation. Patients without evidence of progressive disease
and who could safely undergo major abdominal surgery in the opinion of the operating
surgeon and the multidisciplinary treatment group were brought to the operating room for
planned resection of the primary tumor.
Pancreatic resection was performed in a standard fashion, as previously described.31,32
Tangential or segmental resection of the superior mesenteric vein, portal vein, or SMPV
confluence was performed when the operating surgeon could not separate the pancreatic
head or the uncinate process from these vessels without leaving gross tumor on the vessel or
risking uncontrolled venotomy. When limited involvement of the common hepatic artery
was identified, segmental resection of this vessel was performed with primary anastomosis
or interposition grafting.
Histopathologic Evaluation of Surgical Specimens
For the purposes of this report, the original pathology report of each patient was rereviewed
in detail. When available, the original histopathology slides of all patients who survived at
least 5 years were rereviewed by a single faculty gastrointestinal pathologist (H.W.) to
confirm the diagnosis. Pretreatment cytologic or histologic biopsy samples from patients
who were reported to have experienced a complete response to neoadjuvant therapy were
also rereviewed.
Since July 1990, a standardized system for the pathologic evaluation of PD specimens has
been used at our institution. This system enabled prospective evaluation of the status of the
SMA margin of resection. The technique for assessment of the SMA margin was the same
regardless of whether vascular resection was performed. Early in our institutional
experience, the SMA margin was evaluated by microscopic examination of an en face
section.33 Beginning in January 2000, the SMA margin was evaluated according to the
American Joint Commission on Cancer (AJCC) Cancer Staging Manual (6th edition)
guidelines.34 Margins were designated R0 if no tumor cells were identified at all of the
resection margins. The designation R1 was applied if tumor cells were present at the SMA
margin or at the final common bile/hepatic duct or pancreatic transection margin (these later
two margins were often resected again in the event of a positive frozen-section diagnosis).
Tumor size was calculated by the pathologist by measuring the maximum gross transverse
diameter of the tumor after resection. This measurement was difficult to determine in some
patients after preoperative therapy because the tumor was often hard to distinguish from
uninvolved adjacent pancreatic parenchyma by gross examination. Although histopathologic
grade was recorded for each cancer, this pathologic factor was not included in the univariate
or multivariate analyses because of the relatively subjective nature of the assessment of
tumor grade.
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Follow-Up and Statistical Analysis
After completion of all treatment, patients were evaluated every 3–4 months by physical
examination, chest radiography, and abdominal CT scan. In patients without evidence of
disease after 2 years of follow-up, evaluations were reduced to 6-month intervals. All but
five patients evaluated during the time period under study had a minimum of 5 years of
follow-up unless they died within 5 years of their date of diagnosis. The remaining five
patients (detailed below) were foreign and were lost to follow-up within 5 years from
diagnosis. These five patients were excluded from the analysis.
The development of a new low-density mass in the region of the resected pancreas or root of
mesentery was considered evidence of local recurrence, even in the absence of symptoms or
biopsy confirmation. Radiographic evidence of a new low-density mass in the liver or lungs
was typically considered evidence for distant recurrence. Peritoneal recurrence was defined
as the development of new ascites on physical examination or CT. When radiographic
findings were consistent with recurrent cancer, biopsy was rarely performed except in
patients with late recurrence of disease (>5 years), particularly when first identified in the
lung; in these patients, biopsy was often performed to rule out a second primary lung cancer.
Only the first site or sites of recurrent disease was documented.
Patients who died after a confirmed recurrence were assumed to have died of PC (DWD)
unless otherwise noted. Patients who died without recurrence were considered to have died
of another cause (DOC), either if another cause was documented or if another cause was not
documented but the patient had been found on serial evaluation to have no evidence of
disease (NED) within 3 months of death. Patients in whom cause of death was not recorded
and in whom time of death from last clinical follow-up exceeded 3 months were classified as
having died of unknown cause. Patients alive at the last evaluation were classified either as
NED or as alive with disease (AWD) if recurrence was previously documented.
All follow-up was measured from the date of histopathologic diagnosis. Overall survival
was calculated by the date of death or last contact. Disease-specific survival was calculated
by the date of death with disease; patients who died of another or unknown cause were
censored. The Kaplan-Meier method was used to generate survival curves by clinical
characteristics. Multiviariate logistic regression analysis was conducted to identify factors
associated with overall survival of ≥5 years. Variables that were significant on univariate
analysis at P ≤ .25 were included in the multivariate analysis. All statistical tests were two
tailed, with a significance level of P < .05. SPSS software version 15.0 (SPSS, Chicago, IL)
was used for all statistical analyses.
RESULTS
Between 1990 and 2002, a total of 2,217 patients with biopsy-confirmed PC were evaluated
at our institution. Among these, the initial radiographic evaluation revealed locally advanced
or metastatic disease in 610 and 992 patients, respectively. Of the remainder, 337 (15% of
2,217 total patients) ultimately underwent surgical resection for a resectable or borderline
resectable primary PC. Follow-up for survival was complete for a minimum of 5 years or to
the date of death (if death occurred before 5 years) in 332 (99%) of the 337 patients. The
remaining five patients were lost to follow-up at a median of 9.8 months from diagnosis and
were excluded from analysis. Each of these five patients came from outside the United
States and had tumors of the pancreatic head or uncinate process. None had previously been
administered chemotherapy or chemoradiation; three had undergone prior laparotomy with
an unsuccessful attempt at tumor resection. At referral, one patient underwent an R0 PD and
was found to have disease-negative lymph nodes. The remaining four patients received
neoadjuvant treatment before PD: three underwent an R0 resection and had negative lymph
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nodes, one had a positive SMA margin, and four had positive regional lymph nodes. One of
the five patients lost to follow-up required vascular resection at the time of PD.
Of the 332 patients whom we could evaluate, 91 (27%) survived at least 5 years, and 241
(73%) patients died within 5 years of diagnosis. Original histopathology slides of the tumors
from 86 of the 91 patients who survived 5 years were available for repeat review. Pathology
repeat review led to a change in the diagnosis of four (5%) patients, including a change to
adenocarcinoma arising in the distal common bile duct in two patients, adenocarcinoma
arising within an intraductal papillary mucinous neoplasm in one patient, and a mixed
adenocarcinoma/neuroendocrine carcinoma in one patient. This last patient was left in the
study population, and the other three patients were excluded from further analysis. The
original diagnosis of PC of ductal origin was confirmed in the remaining 82 patients (of 86
with available slides). After excluding 3 of the 4 patients in whom the diagnosis was
changed, the final study population included 329 patients: 88 (27%) who survived 5 years
(83 of whom underwent pathology repeat review), and 241 (73%) who did not survive 5
years. Systemic chemotherapy and/or chemoradiation had been administered to 21 patients
(6%) before referral, and 48 patients (15%) had undergone prior laparotomy with an
unsuccessful attempt at tumor resection.
Demographic and treatment factors are listed in Table 1. Univariate analysis revealed no
difference between cohorts of patients who did and did not survive 5 years in terms of sex,
age, type of operation performed and the need for vascular resection, operative blood loss,
length of hospital stay, use of neoadjuvant or adjuvant therapy, or tumor size. However,
patients who survived 5 years were less likely to have undergone attempted tumor resection
before referral and were more likely to have undergone a margin-negative (R0) resection
and to have disease-negative lymph nodes. Surgical margins were grossly negative in all
patients; 52 (16%) of 329 total patients were found to have microscopically positive (R1)
margins in the final pathology report. Among 49 R1 PDs, microscopically positive margins
included the SMA margin (n = 44), the final pancreatic transection margin (n = 10) and the
final common bile/hepatic duct margin (n = 2). In addition, one patient who underwent total
pancreatectomy had a microscopically positive SMA margin, and two patients who
underwent distal pancreatectomy had a microscopically positive pancreatic transection
margin. The median number of lymph nodes examined in the pathology specimen was 15
(range, 0–48). In patients with node-positive disease, the median number of positive lymph
nodes was 2 (range, 1–21). Importantly, only 25 (8%) of the 329 patients underwent surgery
alone without any form of additional therapy; 301 (91%) received either preoperative or
postoperative chemotherapy or chemoradiation. In three patients who did not receive
neoadjuvant therapy, the administration of postoperative therapy could neither be confirmed
nor excluded.
Survival
The median overall survival of the 329 patients was 23.9 months (95% confidence interval
[95% CI] 20.89, 26.9). Eighty-eight patients survived 5 years from diagnosis for an actual 5-
year survival rate of 27% (Fig. 1a). At last follow-up, 275 (84%) of 329 patients had died,
including 4 (1%) who died in the perioperative period. The median follow-up for the 54
patients who were still alive at last follow-up was 7.6 years (range, 5.0–16.1 years).
The 88 patients who survived 5 years or longer had a median overall survival of 11.3 years.
At last follow-up, 34 of these 5-year survivors had died and 54 remained alive. Of the 34
patients who had died, 17 were classified as DWD and 11 were classified as DOC and had
no evidence of PC at the time of death. Six patients died of unknown cause. Of the 54
patients who were alive at last follow-up, 51 were NED and 3 were AWD. The 241 patients
who did not survive 5 years included the 4 perioperative deaths, 208 patients DWD, 19
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DOC, and 10 in whom the exact cause of death could not be determined. The disease-
specific survival for the entire population was 26.5 months (95% CI 23.1, 29.9) (Fig. 1b).
Of the 329 total patients in this analysis, 145 patients treated between 1990 and 1998 had a
potential of 10 years of follow-up. Among these, 20 patients survived 10 years, yielding a
10-year actual survival rate of 14%. At last contact, 10 of the 20 patients were NED, 7 were
DOC, and in 3, the exact cause of death could not be determined; these 3 patients were last
documented NED at 10.3 years, 11.1 years, and 11.6 years after diagnosis. No 10-year
survivor died with documented recurrent PC at the time of death.
Treatment and histopathologic clinical factors were compared between patients who did and
did not survive 5 years by a multivariate logistic regression model constructed from
variables that were significant on univariate analysis at P ≤ .25 (Table 2). By use of this
model, we found that negative lymph nodes (odds ratio 1.92, 95% CI 1.13, 3.27, P = .02)
and lack of a history of prior attempt at resection (odds ratio 4.05, 95% CI 1.97, 11.94, P = .
01) were statistically significant prognostic factors associated with 5-year survival.
Disease Recurrence
Recurrent PC was documented in 229 (70%) of the 329 patients at 244 sites of first
recurrence (Fig. 2). Of these 229 patients, 225 were DWD and 3 were AWD at last contact.
One additional patient experienced recurrence but was classified as DOC at the time of
death; this patient developed histopathologically confirmed metastatic PC isolated to the left
frontal lobe of the brain 21 months after diagnosis, underwent craniotomy and
metastasectomy, and ultimately died 9.5 years after her original diagnosis. Cause of death
was renal failure unrelated to her cancer. All confirmed cases of recurrence occurred within
6.7 years of diagnosis and 211 (92%) of the 229 patients who experienced recurrence did so
within the first 3 years after diagnosis. Death with disease occurred at a median of 5.6
months after the date of first recurrence (range, .1–57.1 months) in the 225 patients who
died with documented recurrent PC.
Among the 229 patients whose disease recurred, the most common sites of first recurrence
were liver (n = 107; 47%), lung (n = 50; 22%), tumor bed and regional lymph nodes (n = 39;
17%), and peritoneum (n = 30; 13%) (Fig. 2). Recurrence within the first 3 years of
diagnosis most commonly manifested as hepatic metastasis: 104 (46%) of 226 sites of first
recurrence within the first 3 years of diagnosis versus 3 (17%) of 18 sites of first recurrence
after 3 years from diagnosis. In contrast, recurrent disease identified after the third year was
most common in the lungs: 10 (56%) of 18 sites of first recurrence after the third year versus
40 (18%) of 226 sites of first recurrence within the first 3 years.
Among the 88 patients who survived 5 years, 21 patients experienced recurrence (Table 3).
Within the first 5 years of diagnosis, 14 (67%) of 21 patients recurred at 15 sites: liver (n =
3; 21%), lung (n = 7; 50%), tumor bed or regional lymph nodes (n = 2; 14%), and other sites
(n = 3; 21%). After 5 years of follow-up, we documented an additional seven patients with
first sites of recurrent PC in the lung (n = 6; 86%), peritoneum (n = 1; 14%), or dermis (n =
1; 14%). For each of these late recurrences, a tissue biopsy was performed to exclude a
second primary cancer. In total, of 21 patients whose disease recurred and who survived 5
years, only 3 (14%) experienced recurrence recurred in the liver and only 2 (10%)
experienced local recurrence. Most first recurrences in the 21 patients who survived 5 years
were located in the lung (n = 13; 62%), particularly when the recurrence developed late. In
contrast, of the 208 patients who experienced recurrence and who did not survive 5 years,
recurrences occurred in the liver (n = 104; 50%), tumor bed and regional lymph nodes (n =
38; 18%), lung (n = 37; 18%), and peritoneum (n = 28; 14%) (Table 4).
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DISCUSSION
Of 329 consecutive patients who underwent surgical resection of their primary PC, 88 (27%)
survived 5 years, which to our knowledge is the highest actual survival rate reported (Table
5). We attribute this result to the use of objective criteria for the selection of patients for
surgery, a standardized approach to the technical aspects of the operation (to minimize local
recurrence), an institutional emphasis on multimodality therapy, and the frequent use of
neoadjuvant treatment sequencing, which may result in avoiding surgery in patients most
susceptible to early disease recurrence. However, it is important to note that patients
included in this report were treated between 1990 and 2002 to allow for a minimum follow-
up of 5 years; patients treated more recently may do even better with the progress (albeit
modest) that has resulted from the development and use of systemic chemotherapy and the
integration of systemic therapy, chemoradiation, and surgery into contemporary treatment
schemas.
The selection of patients for surgery was influenced by the use of high-quality pretreatment
cross-sectional imaging with CT, treatment sequencing that often involved neoadjuvant
therapy, and the clinical assessment of patients by experienced oncology specialists. We
used objective CT-based criteria to define the extent of disease as resectable, borderline
resectable, locally advanced, or metastatic.29 Importantly, local tumor resectability was
determined preoperatively, and surgery was considered only in patients with resectable or
borderline resectable disease. In the absence of extrapancreatic metastatic disease, an
aggressive approach was taken to venous resection and reconstruction when isolated venous
involvement was the only impediment to an otherwise complete gross resection.18 In
contrast, we did not attempt resection in patients with locally advanced, stage III disease in
whom a gross (R0 or R1) resection was not possible. In patients who undergo an incomplete
gross (R2) resection, length of survival is not improved in comparison to cases of stage III
disease managed without surgery in patients who receive chemotherapy and/or
chemoradiation.35 Indeed, among patients with advanced disease8–11,13 and among those
who underwent a grossly incomplete (R2) resection11,13 who were explicitly included in
prior reports of long-term survival after pancreatic resection, only a single 5-year survivor
(reported to have had stage III disease) was identified.8 Accurate pretreatment staging and
multidisciplinary consensus with regard to resectability (based on CT images) is something
that can—and should—be performed at all medical centers that offer surgical treatment for
PC.36 Such a practice will minimize the inappropriate use of surgery in patients with
advanced disease and will ensure that all patients with resectable disease are considered for
surgery, we hope as part of a multimodality treatment program.
Consensus is growing that chemotherapy with or without radiotherapy combined with
surgery results in higher rates of survival in patients with resectable PC than surgery
alone.2,3,15,37–39 In this report, 91% of patients received either neoadjuvant or adjuvant
therapy, and most patients were enrolled onto a clinical trial. Importantly, neoadjuvant
therapy was delivered to 77% of all patients. The cytotoxic effect of such induction therapy
is likely responsible for the lower-than-expected rates of microscopically involved lymph
nodes and positive resection margins observed in the surgical specimens.30,40 The
administration of chemotherapy and/or chemoradiation before surgery also enriches the
population of patients selected to undergo pancreatic resection with those most likely to
have a favorable outcome compared with patients treated with surgery first. In our most
recent two clinical trials of neoadjuvant therapy for patients with stage I and II PC, 30% of
patients who began neoadjuvant therapy did not undergo PD as a result of disease
progression, evolving medical comorbidities, or a decline in performance status.26,27 These
patients, who had a median survival of <12 months, include those patients who would not
have received a survival benefit from surgery as a result of the presence of metastatic
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disease that was radiographically occult at the time of pretreatment staging, and those with
medical comorbidities that were also not readily apparent at the time of diagnosis.
Neoadjuvant treatment sequencing accurately identified those patients who would otherwise
have experienced early postoperative recurrence and those who may have an increased risk
for perioperative complications; such patients did not undergo pancreatectomy. Surgery-last
treatment sequencing benefits both the patients who undergo resection of their primary
tumor and those who do not.
We recently reported our institutional experience with patients having borderline resectable
pancreatic cancer, a prospectively identified subset of AJCC stage III disease, in whom a
neoadjuvant strategy is particularly important.17,29 At our institution, three clearly defined
groups of patients were classified as borderline resectable: (1) patients with strictly defined
borderline resectable local tumor anatomy, predominantly arterial abutment, as described
above; (2) patients with localized tumors who also had additional CT findings suspicious but
indeterminate for metastatic disease; and (3) patients with a marginal but potentially
recoverable performance status or extensive comorbidities requiring a prolonged evaluation
that precluded immediate major abdominal surgery. In each of these three groups, we took
advantage of the theoretical benefits of neoadjuvant treatment sequencing over a long time
period (minimum of 4 months) of systemic chemotherapy and chemoradiation. Serial
restaging evaluations at 2-month intervals selected patients for additional therapy and
ultimately surgery; only patients with an acceptable performance status and no evidence of
disease progression at the end of neoadjuvant therapy underwent surgery.
In our previously published series of 160 patients treated with this approach, 41% of patients
completed all therapy, including surgery; 56% of resected specimens had a pathologic
response to treatment characterized by <50% tumor viability, and 94% of resections resulted
in microscopically negative (R0) margins. The 41% of patients who completed all therapy
including surgery had a median survival of 40 months. Median survival was 13 months for
the 59% of patients who developed disease progression or evolving medical comorbidities.
Patients with borderline resectable disease are at high risk for having CT-occult distant
metastases, likely are at higher risk for a positive resection margin than patients with stage I
or II PC, and often require a larger, more complex, and higher-risk operation to remove their
primary tumor. When the magnitude of the operation and the risk for recurrence are both
increased, neoadjuvant treatment sequencing becomes more attractive as a strategy to more
precisely select patients who will benefit from pancreatectomy.
Patients who did not receive neoadjuvant therapy were routinely encouraged to receive
postoperative adjuvant therapy, either, typically as part of a clinical trial. However, a
number of factors may delay or prohibit the administration of adjuvant therapy in the
postoperative patient. Indeed, a recent investigation of national practice patterns for
multimodality therapy use reported that <50% of patients who underwent pancreatectomy at
high-volume centers received chemotherapy or chemoradiation, although the reasons for the
low rate of multimodality therapy were unclear.15 These data are supported by two recently
published large single-institution experiences in which adjuvant therapy was received by
only 44% and 60% of eligible patients who had received a surgery-first treatment strategy
for PC.41,42 In a previous study from our institution, we reported that 26% of patients who
underwent PD without any prior treatment did not receive intended adjuvant therapy.21
Patients did not receive postoperative adjuvant therapy for reasons that could be classified
into three categories: treatment related (surgical complications, delayed recovery), disease
related (disease progression), and patient related (advanced age, marginal preoperative
performance status, medical comorbidities, patient refusal). For those patients with an
Eastern Cooperative Oncology Group (ECOG) performance status that we would consider
of marginal acceptance for major surgery (in the lower range of ECOG 2), a surgery-first
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strategy is likely to be associated with both an increased risk for complications and a high
likelihood of not receiving any additional oncologic treatment. An understanding of the
complexity of delivering multimodality therapy to patients of advanced age who require a
large cancer operation and often have marked medical comorbidities will become even more
important as our systemic therapies for PC improve.
The present report failed to reveal an association between the administration of neoadjuvant
or adjuvant therapy and long-term survival. However, this is not surprising, given the high
rate of combined modality treatment among all patients, the relatively modest patient
numbers, and the retrospective design of this study. Only 7% of patients did not receive
systemic therapy and/or chemoradiation in addition to surgery.
The frequent use of neoadjuvant therapy and the standardized approach to surgery likely
influenced the low rate of margin positivity (16%). In a previous report from our institution
focusing specifically on the incidence of R1 resections and the implications of this
pathologic finding, the frequency of a positive SMA margin was less in those patients who
received preoperative chemoradiation (13%) compared with those patients taken directly to
surgery (19%).19 This difference was not statistically significant but was clinically
important, given the selection bias in favor of going straight to surgery, without neoadjuvant
therapy, in patients with smaller tumors whose theoretical risk for an R1 resection was
thought to be low. In fact, such carefully selected patients actually had a higher frequency of
having a disease-positive SMA margin on final pathologic analysis of the PD specimen.
This finding lends further support to the observation that PC can extend along visceral
perineural fibers to the SMA and a positive microscopic margin can be found when the
grossly visible tumor seems to be separate from the lateral wall of the SMA. Both
multimodality therapy and proper surgical technique may be necessary to minimize the risk
for a positive SMA margin and thereby reduce the risk of local recurrence. For example, all
tissue to the right of the SMA should be removed with the PD specimen; the application of a
stapling devise or a series of clamps without visible identification of the SMA should be
avoided. In this report, local recurrence was seen radiographically in 42 (13%) of the 329
patients. Local control is clearly necessary (but not sufficient) for long-term survival, and as
our systemic therapies improve, the importance of maximizing local disease control at the
time of initial treatment may provide further enthusiasm for neoadjuvant chemoradiation.
In this report, factors adversely associated with long-term survival on multivariate analysis
included the presence of metastatic disease in regional lymph nodes and a previous attempt
at tumor resection before referral to our institution. Of the 88 five-year survivors, only five
patients had undergone an unsuccessful attempt at tumor removal before referral. However,
48 patients had undergone laparotomy for planned pancreatectomy before referral; the effect
of an unsuccessful prereferral laparotomy was profound and something not widely discussed
in the literature. The importance of carefully selecting patients for PC surgery who are
compatible with the skill set of the surgeon cannot be overstated.
Of the 88 five-year survivors, 32 (36%) were found to have pathologically involved lymph
nodes. In fact, of the 157 node-positive patients, 32 (20%) survived 5 years. To what degree
the favorable outcome in patients with N1 disease is related to the use of multimodality
therapy cannot be accurately determined. One would assume that the selection bias
introduced by neoadjuvant treatment sequencing combined with the frequent use of systemic
chemotherapy is partly responsible for this encouraging result. In any event, the finding that
20% of node-positive patients were alive at 5 years after diagnosis would argue against
routine lymph node biopsy at the time of surgery because node-positive disease does not
seem to represent a contraindication to surgical resection of the primary tumor when
performed as part of a multimodal treatment strategy.
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Finally, the incidence and pattern of disease recurrence warrants further comment. As
demonstrated in Fig. 2, most recurrences occurred early and developed in the abdomen
(largely in the liver). In contrast, late recurrences developed predominantly in the lung. This
pattern of recurrence supports the use of abdominal CT or magnetic resonance imaging for
routine follow-up, particularly within the first 3 to 5 years after definitive treatment.
Although not analyzed in this report, we found that serum levels of CA 19-9 are frequently
also helpful, unless undetectable (indicative of individuals with the Lewis a–b blood group
antigen who do not synthesize CA 19-9). In this report, the latest cancer recurrence was
identified 6.7 years from diagnosis, and the latest cancer-related death occurred at 7.6 years.
These findings support prior observations that 5-year survival does not always equate with
cure for patients with this disease.9,13 However, the plateau of our disease-specific survival
curve (Fig. 1b) does suggest that patients free of disease at 7 to 8 years after diagnosis are at
very low risk for death from recurrent PC. For patients who died of recurrent disease within
5 years, death occurred at a median of 5.5 months (range, .1–36.5 months) after recurrence
was identified. In contrast, of the 17 five-year survivors who died of recurrent PC, death
occurred at a median of 15 months (range, .7–51 months) after the diagnosis of recurrence
(Table 3). These data suggest that 5-year survivors who are not cured are characterized by
an as-yet undefined tumor biology that includes a predisposition for pulmonary metastases
and a more indolent form of disease progression.
In conclusion, we report a consecutive series of patients with resectable (stage I, II) and
borderline resectable (stage III) PC who were treated with curative intent to include surgical
resection of the primary tumor. The favorable long-term survival reported herein reflects
what is possible when a well-selected group of patients are carefully staged with high-
quality imaging and treated in a disease site-specific multidisciplinary program with state-
of-the-art surgery, combination chemotherapy, and radiotherapy. Future progress in the
treatment of patients with PC will emphasize both the optimization of our current
technologies and treatments, as well as the development of novel and more effective
systemic therapies.
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FIG. 1.
(a) Actual overall and (b) disease-specific survival of patients with resectable or borderline
resectable pancreatic adenocarcinoma who were evaluated at M. D. Anderson Cancer Center
between 1990 and 2002 and who underwent resection
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FIG. 2.
Frequency, location, and timing of disease recurrence after resection for patients with
resectable and borderline resectable pancreatic adenocarcinoma
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TABLE 1
Univariate analysis of demographic and treatment-related factors for the 329 consecutive patients who were
evaluated for pancreatic adenocarcinoma between 1990 and 2002 and underwent resection
Clinical factor Total Survival
<5 years
Survival
≥5 years
P value
Patients (n) 329 241 88
Demographics
Sex, n (%) .34
    Male 190 (58) 143 (59) 47 (53)
    Female 139 (42) 98 (41) 41 (47)
Age (years) .70
    Median (mean) 64 (63) 64 (63) 63 (62)
    Range 30–85 39–82 30–85
Surgery
Type of operation, n (%) .26
    Pancreaticoduodenectomy 302 (92) 219 (91) 83 (94)
    Distal pancreatectomy 20 (6) 15 (6) 5 (6)
    Total pancreatectomy 7 (2) 7 (3) 0 (0)
Reoperative, n (%) 48 (15) 43 (18) 5 (6) .006
Vascular resection, n (%) 108 (33) 83 (34) 25 (28) .30
    Superior mesenteric or portal vein 101 (31) 76 (32) 25 (28)
    CHA 9 (3) 7 (3) 2 (2)
    Inferior vena cava 4 (1) 4 (2) 0 (0)
Operative blood loss (ml) .08
    Median (mean) 950 (1289) 1000 (1374) 900 (1057)
    Range 100–18,000 100–18,000 125–3600
Length of stay (days) .14
    Median (mean) 12 (15) 13 (15) 11 (13)
    Range 5–108 5–108 6–41
Additional therapy
Neoadjuvant treatment, n (%) 253 (77) 188 (78) 65 (74) .43
    Chemotherapy 36 (11) 27 (11) 9 (10)
    Chemoradiation 248 (76) 185 (77) 63 (72)
Adjuvant treatment, n (%) 59 (18) 42 (18) 17 (20) .68
    Chemotherapy 19 (6) 15 (6) 4 (5)
    Chemoradiation 49 (15) 34 (14) 15 (17)
Surgery alone, n (%) 25 (8) 18 (7) 7 (8) .95
Tumor histopathology
Tumor size (cm) .09
    Median (mean) 3.0 (3.0) 3.0 (3.1) 3.0 (2.8)
    Range .2–13 .2–13 .3–8.0
Margin status, n (%) .04
    R0 277 (84) 197 (82) 80 (91)
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Clinical factor Total Survival
<5 years
Survival
≥5 years
P value
    R1 52 (16) 44 (18) 8 (9)
Lymph node status, n (%) .01
    N0 172 (52) 116 (48) 56 (64)
    N1 157 (48) 125 (52) 32 (36)
Lymph node ratio, n (%)a .05
    0 171 (52) 115 (48) 56 (64)
    0–.2 93 (28) 72 (30) 21 (24)
    .2–.4 44 (13) 35 (15) 9 (10)
     >.4 20 (6) 18 (7) 2 (2)b
P comparison between survival cohorts
a
Ratio of the number of positive lymph nodes to the number examined
b
Adenocarcinoma identified in 6 of 12 nodes in one patient and 1 of 2 in the other
CHA common hepatic artery
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TABLE 2
Multivariate analysis of clinicopathologic factors associated with 5-year survival
Prognostic variable No. of
patients
Odds
ratio
95% CI P value
No prior attempt at resection 281 4.05 1.97, 11.94 .01
Lymph nodes negative (N0) 157 1.92 1.13, 3.27 .02
R0 resection 277 1.96   .86, 4.45 .11
Factors included in the multivariate model included those significant on univariate analysis at P ≤ .25: tumor size, length of stay, previous attempt
at tumor resection, R status, nodal status, and EBL estimated blood loss
95% CI 95% confidence interval
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TABLE 3
Timing and first site or sites of recurrent disease in 21 five-year survivors whose disease recurred
Patient No. Site of first
recurrence
Time to
recurrence
(months)
Recurrence to
last follow-up
(months)
Overall survival
(months)
Current
status
1 Lunga 10 54 64 DWD
2 Liver 12 56 68 DWD
3 Locoregionala 13 47 60 DWD
4 Lunga 16 57 73 DWD
5 Braina 21 114 135 DOC
6 Abdominal walla 25 41 66 AWD
7 Liver, lung 29 37 66 DWD
8 Livera 42 23 65 DWD
9 Locoregionala 43 27 69 DWD
10 Lunga 47 23 70 AWD
11 Lunga 49 20 69 DWD
12 Lunga 57 9 65 AWD
13 Lung 57 3 60 DWD
14 Peritoneuma 58 7 65 DWD
15 Lunga 70 15 85 DWD
16 Lunga 71 1 71 DWD
17 Dermisa 71 1 73 DWD
18 Lunga 76 12 88 DWD
19 Lunga 78 12 91 DWD
20 Lung,a Peritoneum 80 4 83 DWD
21 Lunga 80 11 91 DWD
DWD dead with disease, DOC dead of other cause, AWD alive with disease
a
Histopathologically verified
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TABLE 4
Comparison of sites of first recurrence between 5-year survivors and patients who did not survive 5 years
Characteristic Survival
<5 years
(n = 241)
n
Survival ≥5 years (n = 88)
n Recurrence
<5 years (n)
Recurrence
≥5 years (n)
No. of patients whose disease recurred 208 21 14 7
Site of first recurrencea
    Liver 104 (50) 3 (14) 3 (21) 0
    Lung 37 (18) 13 (62) 7 (50) 6 (86)
    Locoregional 38 (18) 2 (10) 2 (14) 0
    Peritoneum 28 (13) 2 (10) 1 (7) 1 (14)
    Abdominal wall/dermis 1 (1) 2 (10) 1 (7) 1 (14)
    Brain 0 1 (5) 1 (7) 0
    Bone 3 (1) 0 0 0
    Other 6 (3) 0 0 0
a
Totals may exceed 100% as a result of multiple sites of first recurrence in several patients
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TABLE 5
International series of long-term survivors after treatment for pancreatic adenocarcinoma
Series No. of
patients
PD
(%)
Stages
included
Adjuvant
treatment
(%)
R0
(%)
R1/R2
(%)
N1
(%)
Vascular
resection
(%)
Median
OS (Mo)
Actual 5-
year
survivors,
n (rate %)
MDACC (current study) 329 92 PR, BR 91 84 16/0 48 33 24 88 (27)
Mayo Clinic13 357 100 PR, LA, M 77 77 18/5 49 13 17 62 (17)
Johns Hopkins12 564 100 NR NR NR NR NR NR NR 96 (17)
Memorial Sloan-Kettering
Cancer Center9
618 85 PR, M 21 73 27/0 NR 0 NR 75 (12)
University of Indiana11 226 90 PR, LA 34 70 28/2 56 6 13   9 (4)
Seoul National University,
Korea10
123 81 PR, LA, M 49 76 24a 54 14 15 11 (9)
Mount Sinai Hospital,
Toronto8
123 91 PR, LA 21 NR 15b 43 10 14 18 (15)
PD pancreaticoduodenectomy, PR potentially resectable, BR borderline resectable, LA locally advanced, M metastatic, NR not reported, OS overall
survival, N1 positive regional lymphadenopathy
a
No distinction made between R1 and R2 resections
b
No distinction made between R1 and R2 resections; number of R0 resections not stated
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